Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* an age above 18 years~* consultation within 48 hours following a risk of HIV transmission (blood or sexual contact)~* indication for HIV post-exposure prophylaxis (according to French guidelines)~* person able to understand the nature of the study~* person who signed his consent form to participate in the study~Exclusion Criteria:~* person exposed to HIV risk from person infected by HIV, whose therapeutic history justifies the prescription of another combination of antiretroviral drugs~* contraindications to the prescription of Genvoy~* other medical contraindications~* person infected by hepatitis B virus~* pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genvoya (Type: EXPERIMENTAL): Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).